# US 2021/0196688 A1 · Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196688 A1
- Document ID: US20210196688A1
- Status: Published application
- Kind: A1
- Application number: 17/096,637
- Filed: 2020-11-12
- Published: 2021-07-01
- Earliest claimed: 2016-10-13
- Assignees: Retrophin, Inc.
- Applicants: Retrophin, Inc.
- Inventors: Radko Komers; Alvin Shih
- Web page: https://patentgrep.com/patent/US20210196688A1

## CPC

- A61K 31/422: not condensed and containing further heterocyclic rings
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treatment comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I) or pharmaceutically acceptable salt thereof, are provided.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A method of treating a kidney disease or disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having structure (I),
or a pharmaceutically acceptable salt thereof, wherein said subject has a urine protein to creatinine (“UP/C”) ratio greater than 1.5 g/g prior to administration of said pharmaceutical composition.

### Claim 46 (depends on 45)

The method according to claim 45, wherein said subject has an estimated glomerular filtration rate greater than 30 ml/min prior to administration of said pharmaceutical composition.

### Claim 47 (depends on 45)

The method according to claim 45, wherein said pharmaceutical composition is administered to said subject
(i) in an amount sufficient to achieve a UP/C ratio of less than or equal to 1.5 g/g; or
(ii) at a dosing regimen sufficient to achieve a UP/C ratio of less than or equal to 1.5 g/g.

### Claim 48 (depends on 45)

The method according to claim 45, wherein said pharmaceutical composition is administered to said subject over an administration period in an amount sufficient to achieve a UP/C ratio of less than or equal to 1.5 g/g for at least a portion of said administration period.

### Claim 49 (depends on 45)

The method according to claim 45, wherein the amount of said compound having structure (I), or pharmaceutically acceptable salt thereof, administered to said subject is from about 50 mg/day to about 1000 mg/day.

### Claim 50 (depends on 45)

The method according to claim 45, wherein the amount of said compound having structure (I), or pharmaceutically acceptable salt thereof, administered to said subject is from 200 mg/day to 800 mg/day.

### Claim 51 (depends on 45)

The method according to claim 45, wherein the amount of said compound having structure (I), or pharmaceutically acceptable salt thereof, administered to said subject is 200 mg/day.

### Claim 52 (depends on 45)

The method according to claim 45, wherein the amount of said compound having structure (I), or pharmaceutically acceptable salt thereof, administered to said subject is 400 mg/day.

### Claim 53 (depends on 45)

The method according to claim 45, wherein the amount of said compound having structure (I), or pharmaceutically acceptable salt thereof, administered to said subject is 800 mg/day.

### Claim 54 (depends on 45)

The method according to claim 45, wherein said administering comprises administering said compound having structure (I), or a pharmaceutically acceptable salt thereof, to said subject at an initial dose and administering said compound having structure (I), or a pharmaceutically acceptable salt thereof, to said subject at a subsequent dose, wherein said subsequent dose is greater than said initial dose.

### Claim 55 (depends on 54)

The method according to claim 54, wherein said initial dose is 400 mg/day and said subsequent dose is 800 mg/day.

### Claim 56 (depends on 54)

The method according to claim 54, wherein said initial dose is 200 mg/day and said subsequent dose is 400 mg/day.

### Claim 57 (depends on 56)

The method according to claim 56, wherein said subject is a child weighing less than 50 kg.

### Claim 58 (depends on 54)

The method according to claim 54, wherein said initial dose is administered for a period of 2 weeks.

### Claim 59 (depends on 54)

The method according to claim 54, wherein the method further comprises measuring the blood pressure of said subject before administering said subsequent dose.

### Claim 60 (depends on 45)

The method according to claim 45, wherein said compound has structure (I).

### Claim 61 (depends on 45)

The method according to claim 45, further comprising administering to said subject one or more additional therapeutic agents.

### Claim 62 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is a disorder related to glomerular function.

### Claim 63 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is focal segmental glomerulosclerosis (FSGS).

### Claim 64 (depends on 63)

The method according to claim 63, wherein said FSGS is primary FSGS.

### Claim 65 (depends on 63)

The method according to claim 63, wherein said FSGS is secondary FSGS.

### Claim 66 (depends on 63)

The method according to claim 63, wherein said FSGS is genetic FSGS.

### Claim 67 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is IgA nephropathy.

### Claim 68 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is idiopathic membranous nephropathy (IMN).

### Claim 69 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is diabetic nephropathy.

### Claim 70 (depends on 45)

The method according to claim 45, wherein said kidney disease or disorder is lupus nephritis.
